CGT · 혈액암 (AML/ALL)

360개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved360 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

Chimeric Antigen Receptor Modified T cells Targeting CD19 (Chimeric Antigen Receptor Modified T cells Targeting CD19)

Leukemia; Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleNelson HamerschlakPhase 1

Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 (Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleWashington University School of…Phase 2

Cytokine-induced memory-like NK cells (Cytokine-induced memory-like NK cells)

Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy (Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy)

B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleGerman Cancer Research CenterPhase 1

Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion)

Relapsed/Refractory Acute Myeloid Leukemia (AML) · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUniversity of Kansas Medical Ce…Phase 1

DuoCAR20.19.22-D95 (DuoCAR20.19.22-D95)

B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 1

EGFRt/19-28z/4-1BBL CAR T cells (EGFRt/19-28z/4-1BBL CAR T cells)

Chronic Lymphocytic Leukemia (CLL); Relapsed · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleRoswell Park Cancer InstitutePhase 1

EGFRt/19-28z/IL-12 CAR T-lymphocytes (EGFRt/19-28z/IL-12 CAR T-lymphocytes)

Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleBeijing Boren HospitalPhase 1

Efficacy of LCAR-T2C CAR-T cells (Efficacy of LCAR-T2C CAR-T cells)

T Cell Lymphoma; T-cell Leukemia · T Cell Lymphoma

#TCellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 1

Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells (Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells)

Difficult to Treat Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-DCs (EphA2-targeted CAR-DCs)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-T Cells (EphA2-targeted CAR-T Cells)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells (Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells)

Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

FOLR1 CAR T-cells (FOLR1 CAR T-cells)

Recurrent Childhood Acute Myeloid Leukemia; Refractory Childhood Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

14 / 18 pages

← PreviousNext →